UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
UCB received U.S. FDA approval for a once-daily, self-administered autoinjector option for ZILBRYSQ (zilucoplan) in adults with generalized myasthenia gravis who are anti-AChR antibody positive. The approval is the first macrocyclic peptide C5 inhibitor approved as a self-administered subcutaneous autoinjector for gMG and is supported by bioequivalence data showing 99.8% complete dose delivery across 449 administrations.
Key figures
- Drug Name
- ZILBRYSQ (zilucoplan) autoinjector
- Phase Of Trial
- Phase 3b
- Phase3b study n
- 31
- Ucb 2025 revenue
- €7.7 billion
- Bioequivalence study n
- 14
- Complete dose delivery rate
- 99.8%
- Human factors first attempt success
- 90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.